- Details
- Seyed Amiryaghoub M Lavasani presents on the forces exerted during ureteroscopy, a study that aimed to investigate the force applied by urologists when placing ureteral access sheets. Forces below six newtons showed no ureteral injury, while forces above eight led to severe ureteral injuries. Biography: Seyed Amiryaghoub M. Lavasani, Department of Urology, University of California, Irvine, CA Read...
|
- Details
- Ruchika Talwar and Ian Berger discuss a Urology Practice publication on inpatient hematuria evaluation costs in rural for-profit hospitals. Berger reveals that rural for-profit hospitals' costs are significantly higher than their non-profit counterparts, with a price increase of up to 80% for intermediate-risk and about 60% for high-risk evaluations. He attributes this disparity to the lack of com...
|
- Details
- In an informative discussion, Ashish Kamat welcomes Girish Kulkarni to discuss his work around cystectomy-free survival data and the impact of pembrolizumab monotherapy for BCG-unresponsive CIS, as presented in the KEYNOTE-057 trial. Kulkarni highlights the promising results from the trial, stating that patients who responded to the therapy had a median cystectomy-free survival time of 58 months,...
|
- Details
- In a discussion with Andrea Miyahira, Himisha Beltran discusses her team's research on Prostate-Specific Membrane Antigen (PSMA) heterogeneity and regulation in metastatic prostate cancer. The study, led by Martin Bakht, explores the varied levels of PSMA expression in metastases of androgen receptor-positive prostate cancer, as well as the regulation of PSMA in AR-negative and neuroendocrine pros...
|
- Details
- In this conversation, moderated by Ashish Kamat, Paulo Gontero and Gary Steinberg, discuss the treatment and management of intermediate risk, non-muscle invasive bladder cancer (NMIBC). Gontero explains their use of the 2021 EAU guidelines to determine a patient's risk category based on several variables. He emphasizes the complexity of the intermediate risk category and the further need to sub-st...
|
- Details
- In a discussion, Ashish Kamat and Girish Kulkarni delve into the Theralase ® project of intravesical photodynamic therapy for non-muscle invasive bladder cancer. This study, led by Dr. Kulkarni, employs photo-dynamic therapy in a phase two trial for BCG unresponsive bladder cancer, with promising early results. The procedure uses a ruthenium-based photosensitizer and a laser light that creates oxy...
|
- Details
- Matt Cooperberg hosts a conversation with Drs Tracy Downs and Linda McIntire on 'Cultural Complications in Urology', a plenary session at the AUA 2023 annual meeting, which aims to shed light on the biases and barriers faced by marginalized groups in urological care. They explore a variety of patient cases, each highlighting the need for more culturally sensitive practices, with a focus on elimina...
|
- Details
- In this conversation, Ashish Kamat welcomes Andrea Necchi to present his research on the Vesical Imaging-Reporting and Data System (VI-RADS) and its correlation with the pathologic and molecular outcomes of patients undergoing perioperative IO therapy in the context of the PURE-01 study. The study focuses on the evaluation of MRI data and the response to neoadjuvant Pembrolizumab in muscle-invasiv...
|
- Details
- Matt Cooperberg interviews Sigrid Carlsson, Director of Research at MSK for Urology, on the evolution of prostate cancer screening policy and ongoing innovative trials. Carlsson, an integral member of the AUA's screening guideline panel, highlights the transition from the traditional DRE and PSA tests to a new era of risk-stratified screening, aiming to optimize the benefits of PSA testing while m...
|
- Details
- In this conversation, Pedro Barata interviews Toni Choueiri, discussing the combination of cabozantinib with belzutifan in patients with advanced clear cell renal cell carcinoma (RCC). The study focused on two cohorts: one in the refractory setting and the other in the treatment-naive setting. Dr. Choueiri explains the rationale behind combining a HIF-2 inhibitor with a TKI and why cabozantinib wa...
|
